Role of CCL2 in Alcoholic Liver Diseases

Alcoholic Liver Disease Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01128010
• Other study ID #: DD-CCL2
• Status: Completed
• Phase: N/A
• First received: May 20, 2010
• Last updated: May 20, 2010

Study information

• Verified date: December 2002
• Source: Erasme University Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Belgium: Ethics Committee
• Study type: Observational

Clinical Trial Summary

Immune dysregulations, including cytokines and chemokines secretions occurs in alcoholic liver disease. Serum levels and liver expression of CCL2 are increased in patients with alcoholic hepatitis but the role of this chemokine in the pathogenesis of alcoholic liver disease is nevertheless unknown. The aim of the study is to analyze plasma level and liver expression of CCL2 and their relation with liver disease severity and inflammatory infiltrate in our cohort of alcoholic patients. We studied also the association between -2518 CCL2 polymorphism and the severity of alcoholic liver disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

ALD patients

Inclusion Criteria:

• Excess alcohol intake

• Abnormality of liver biopsy compatible with alcoholic aetiology

• Caucasian ethnicity

Exclusion Criteria:

• Presence of any other chronic liver disease

• co-infection with HIV Controls Inclusion criteria

• Caucasian ethnicity

• presence of a disease

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Alcoholic Liver Disease
• Liver Diseases
• Liver Diseases, Alcoholic

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Erasme University Hospital